CBC is restoring its live New Year’s Eve celebration. A year after the national broadcaster cancelled the 2024 countdown due to “financial pressures,” it says the special event is back on the TV schedule to mark the dawn of 2025. Festivities begin Dec. 31 with the one-hour “22 Minutes New Year’s Eve Pregame Special,” a satirical reflection on the events of 2024 with the cast of the political comedy series “This Hour Has 22 Minutes.” It will be followed by “Canada Live! Countdown 2025,” a special hosted by news anchor Adrienne Arsenault and singer Jann Arden broadcasting live from Toronto’s Harbourfront Centre, and anchor Ian Hanomansing and comedian Ali Hassan at Vancouver’s VanDusen Botanical Garden. A representative for the CBC says the coast-to-coast show will feature reporters at more than a dozen community events across the country while a countdown to the new year will take place in each of the six time zones. Throughout the seven-and-a-half-hour program, “many Canadian celebrity guests” will appear in live and pre-taped messages. “Canada Live! Countdown 2025” begins at 8 p.m. ET on CBC News Network and CBC Gem with CBC-TV and CBC Radio picking up the feed at 9 p.m. in local markets. Last year, the CBC replaced its live New Year’s Eve programming with a taped Just For Laughs special hosted by comedian Mae Martin. That left Canadians without a homegrown countdown on any of the major networks, which sparked blowback on social media from some viewers. The CBC began its annual specials in 2017 to mark Canada’s sesquicentennial year. Some of the more recent broadcasts were hosted by comedian Rick Mercer and featured fireworks and musical performances in key cities. But when CBC paused those plans last year, it said the show had become “increasingly expensive to produce.” The decision to sideline the program was made shortly after members of Parliament summoned outgoing CBC president Catherine Tait to testify about job cuts and her refusal to rule out bonuses for CBC executives.
Kendrick Lamar is ending 2024 with a bang. The hip-hop heavyweight took fans by surprise when he unveiled his sixth studio album, GNX , without any warning on Friday (Nov. 22). The 12-track project features contributions from SZA — who appears on “Luther” and “Gloria” — Jack Antonoff, Kamasi Washington, Roddy Ricch and more. GNX serves as Lamar’s official follow-up to Mr. Morale & the Big Steppers in 2022, which topped the Billboard 200 with 295,000 total units earned in the first week. In the spring, he contributed a guest verse on Future and Metro Boomin ’s Hot 100 No. 1 single “Like That,” which launched a high-profile rap beef with Drake . The back and forth between the two ultimately culminated in Lamar’s anthemic “Not Like Us,” which not only served to end the feud but also became a longstanding hit, topping the Hot 100 for two nonconsecutive weeks. See latest videos, charts and news See latest videos, charts and news It’s gearing up to be an even more groundbreaking new year for Kenny, who will be taking the stage for the Super Bowl LIX Halftime Show , set to take place on Feb. 9, 2025 in New Orleans, Louisiana. “Rap music is still the most impactful genre to date,” he said at the time of announcement. “And I’ll be there to remind the world why. They got the right one.” The 17-time Grammy winner is also up for seven awards at the 2025 ceremony. “Not Like Us” is up for record of the year, song of the year, best music video, best rap performance and best rap song. Meanwhile, “Like That” is nominated for best rap song and best rap performance. With the release of GNX , fans quickly flooded social media with overwhelmingly positive reactions to the project. “Look me dead in the eyes and tell me Kendrick Lamar isn’t the greatest ever,” one user wrote on X , for example, while another added, “Kendrick just opened his mouth, someone go hand him a Grammy right now.” See below for more fan reactions to Kendrick Lamar’s GNX . Kendrick is the best rapper alive. Period. Everyone 2 seconds into Kendrick Lamar’s new album pic.twitter.com/ed3LrB5izA Kendrick Lamar fans everywhere right now pic.twitter.com/XkY9fgUlhk Kendrick Lamar leaving the studio after recording GNX pic.twitter.com/HJY3GGds1L Kendrick just opened his mouth, someone go hand him a Grammy right now. pic.twitter.com/t0SeMJhTcn look me dead in the eyes and tell me Kendrick Lamar isn’t the greatest ever Eating like this and it’s only the 1st track pic.twitter.com/2R1EQKOAMg
None
Another ex-player rips Jets’ Aaron Rodgers: ‘Arrogance, smugness, entitlement ... I’m just tired of it’LAUSANNE , Switzerland , Dec. 2, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT ), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 34,900 of the Company's common shares to three new employees on December 2, 2024 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08. The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT ) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland , and has operations in London and New Jersey . For more information, please visit https://adctherapeutics.com/ and follow the Company on LinkedIn . ZYNLONTA ® is a registered trademark of ADC Therapeutics SA. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the expected cash runway into mid-2026 the Company's ability to grow ZYNLONTA ® revenue in the United States ; the ability of our partners to commercialize ZYNLONTA ® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA ® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, ADCT 602 as well as early research in certain solid tumors with different targets, linkers and payloads; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS: Investors Marcy Graham ADC Therapeutics [email protected] +1 650-667-6450 Media Nicole Riley ADC Therapeutics [email protected] +1 862-926-9040 SOURCE ADC Therapeutics SA
Opinion editor’s note: Strib Voices publishes a mix of guest commentaries online and in print each day. To contribute, click here . ••• As the fall semester concluded at the University of Minnesota, a different kind of buzz than the usual holiday excitement filled the air: the rush of new artificial intelligence tools. New products launched by Google, OpenAI and other tech giants beg the question: Are we witnessing a genuine educational revolution or simply the latest tech hype cycle? Since ChatGPT’s arrival nearly two years ago, the educational technology world has been saturated with claims that AI will transform learning. But history reminds us: These promises don’t always deliver. As a researcher of learning technologies over the past two decades, I’ve studied the use of technology in education and witnessed cycles of unbridled optimism. Educational radio and TV fell short of their lofty goals. Ιn 2012, Massive Open Online Courses (MOOCs) were hailed as the solution to democratize higher education, but two studies published in one of the world’s most rigorous scientific journals revealed that they disproportionately benefited those who were already more affluent. In 2015, the Chan Zuckerberg Initiative pledged to revolutionize K-12 learning with personalized approaches. Despite considerable investment, these initiatives have also failed to shift K-12 student outcomes in fundamental ways. Education has evolved, but no single technology has delivered the radical transformation it promised. Today, AI is championed as the latest game-changer in education, with advocates arguing that its unique capabilities can make education more effective, efficient and engaging. Proponents suggest AI can provide all kinds of benefits, ranging anywhere from offering one-to-one tutoring to addressing teacher burnout. However, a 2023 UNESCO report warns that AI may exacerbate existing disparities by privileging schools and students with access to high-quality digital infrastructure, leaving others behind. The enthusiasm for improving education is commendable, and our education systems are in desperate need of innovation. But a myopic focus on AI hinders innovation because it sidelines alternative solutions and the scope of conversation among educators, entrepreneurs and policymakers. If AI is so compelling and all-encompassing, why should we look elsewhere for solutions to the challenges that schools and universities are facing? To be sure, AI can be a valuable tool in the service of education. For example, it can help students learn more effectively by tutoring them using scientifically validated methods of studying. Or, it can help them explore possible ways forward when they are stuck, such as when they’re facing writer’s block. What higher education truly needs is a portfolio of solutions. AI can’t do it all. AI can’t fix broken policies, study on behalf of stressed learners or provide financial aid. Initiatives like policy changes, flexible learning opportunities, expanding mental health services on campuses, and offering online options are some of the ways that we can address such problems. These are just a few of the many possibilities for genuine transformation. By taking an expansive approach – one that isn’t limited to AI – we can build a better future for education in Minnesota and beyond. George Veletsianos is professor of Learning Technologies at the University of Minnesota, where he holds the Bonnie Westby Huebner Chair in Education and Technology. He can be reached at georgev@umn.edu and is on BlueSky: @veletsianos.bsky.socialGermany's president said Tuesday that a deadly car-ramming attack on a Christmas market had cast a "dark shadow" over this year's celebrations but urged the nation not to be driven apart by extremists. In his traditional Christmas address, President Frank-Walter Steinmeier sought to issue a message of healing four days after the brutal attack in the eastern city of Magdeburg killed five people and left over 200 wounded. "A dark shadow hangs over this Christmas," said the head of state, pointing to the "pain, horror and bewilderment over what happened in Magdeburg just a few days before Christmas". He made a call for national unity as a debate about security and immigration is flaring again: "Hatred and violence must not have the final word. Let's not allow ourselves to be driven apart. Let's stand together." His words came a day after the far-right Alternative for Germany (AfD) held what it called a memorial rally for the victims in Magdeburg, where one speaker demanded that Germany "must close the borders". Nearby an anti-extremist initiative was held under the motto "Don't Give Hate a Chance". Steinmeier recognised that there was a "great deal of dissatisfaction about politics" in Germany but insisted that "our democracy is and remains strong". A Saudi doctor, Taleb al-Abdulmohsen, 50, was arrested Friday at the scene of the attack in which a rented SUV ploughed at high speed through the crowd of revellers, bringing death and chaos to the festive event. His motive still remains unclear, days after Germany's deadliest attack in years. Abdulmohsen has in his many online posts voiced strongly anti-Islam views, anger at German authorities and support for far-right conspiracy narratives on the "Islamisation" of Europe. News outlet Der Spiegel reported he wrote on social media platform X in May that he expected to die "this year" and was seeking "justice" at any cost. Investigators found his will in the BMW that he used in the attack, the outlet said -- he stated that everything he owned was to go to the German Red Cross, and it contained no political messages. Die Welt daily, citing unnamed security sources, said that Abdulmohsen had been treated for a mental illness in the past, thought this was not immediately confirmed by authorities. - 'You are not alone' - The attack has fuelled an already bitter debate on migration and security in Germany, two months before national elections and with the far-right AfD party riding high in opinion polls. The government is facing mounting questions about possible errors and missed warnings about Abdulmohsen, who was arrested next to the battered BMW sports utility vehicle. Saudi Arabia said it had repeatedly warned Germany about its citizen, who came to Germany in 2006 and was granted refugee status 10 years later. A source close to the Saudi government told AFP that the kingdom had sought his extradition. Chancellor Olaf Scholz's government has pledged to fully investigate whether there were security lapses before the attack. The Saudi suspect has been remanded in custody in a top-security facility on five counts of murder and 205 of attempted murder, prosecutors said, but not so far on terrorism-related charges. German Christmas markets have been specially secured since a jihadist attacker rammed a truck through a Berlin Christmas market in 2016, killing 13 people. The Magdeburg event too had been shielded by barricades, but the attacker managed to exploit a five-metre gap when he steered the car into the site and then raced into the unsuspecting crowd. Steinmeier offered his condolences for relatives of those injured and killed "in such a terrible way" -- when the attack killed a nine-year-old boy and four women aged 45 to 75. "You are not alone in your pain," he told the hundreds of affected families. "The people throughout our country feel for you and mourn with you." (Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.) Track Latest News Live on NDTV.com and get news updates from India and around the world
